Show simple item record

dc.contributor.authorEcemis G.C.
dc.contributor.authorAtmaca H.
dc.date.accessioned2020-06-21T09:36:29Z
dc.date.available2020-06-21T09:36:29Z
dc.date.issued2012
dc.identifier.issn1300-2996
dc.identifier.urihttps://doi.org/10.5835/jecm.omu.29.s1.006
dc.identifier.urihttps://hdl.handle.net/20.500.12712/4428
dc.description.abstractDiabetes mellitus is a chronic disease that is growing in prevalence worldwide. Pharmacologic therapy is often necessary to achieve optimal glycemic control in the management of diabetes. Today's clinicians are presented with an extensive range of oral antidiabetic drugs for type 2 diabetes. These main drug classes include agents that stimulate insulin secretion (sulphonylureas and rapid-acting secretagogues), reduce hepatic glu-cose production (biguanides), delay digestion and absorption of intestinal carbohydrate (?-glucosidase inhibitors) or improve insulin action (thiazolidinediones). We review the mechanism of action, efficacy and side effects of the different classes of oral antidiabetic drugs and discuss the current recommendations for their use. © 2012 OMU.en_US
dc.language.isoturen_US
dc.publisherOndokuz Mayis Universitesien_US
dc.relation.isversionof10.5835/jecm.omu.29.s1.006en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiguanidesen_US
dc.subjectDiabetes mellitusen_US
dc.subjectSecretagoguesen_US
dc.subjectSulphonylureasen_US
dc.subjectThiazolidinedionesen_US
dc.subject?-glucosidase inhibitorsen_US
dc.titleOral antidiabetic agentsen_US
dc.title.alternativeOral antidiyabetik ajanlaren_US
dc.typereviewen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume29en_US
dc.identifier.startpage23en_US
dc.identifier.endpage29en_US
dc.relation.journalOndokuz Mayis Universitesi Tip Dergisien_US
dc.relation.publicationcategoryDiğeren_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record